

***For Immediate Release***

**Asana BioSciences presents pre-clinical data for ASN004, an antibody drug conjugate for the treatment of cancer, at the 5<sup>th</sup> Annual World ADC Summit**

Bridgewater, NJ (USA) October 27, 2014 – Asana BioSciences, LLC (“Asana”, [www.asanabio.com](http://www.asanabio.com)), an independent member of the Amneal Alliance of Companies, today announced its participation in the 5<sup>th</sup> Annual World ADC Summit in San Diego, CA. Roger A. Smith, PhD, Vice-President at Asana BioSciences, presented preclinical data regarding the novel ADC ASN004 for the treatment of various cancers at the conference on October 27, 2014. Dr. Smith explained “ASN004 is a 5T4-oncofetal glycoprotein targeted antibody drug conjugate (ADC) developed in collaboration with Mersana Therapeutics, Inc. that selectively targets tumor cells and employs Fleximer® linker technology. ASN004 shows potent, selective antiproliferative activity in tumor cell lines, and causes complete tumor regression leading to tumor-free survivors in mouse models of human breast, gastric and other cancers. This novel ADC is efficacious at very low doses, well-tolerated and has successfully completed pilot toxicology assessments. ASN004 has the potential to be a very effective treatment for a wide range of cancers.

“We are pleased to report some of the preclinical research findings for ASN004, the lead ADC asset from our discovery and early development pipeline,” said Sandeep Gupta, PhD, Co-founder and Chief Executive Officer at Asana BioSciences. “We are excited about this potential ‘best-in-class’ molecule and look forward to advancing it into clinical development in the near future.”

**About Asana BioSciences, LLC**

Asana BioSciences, LLC, an independent member of the Amneal Alliance of Companies, is a research and development company based in Bridgewater, NJ specializing in the discovery and development of new chemical and biological entities. Asana’s portfolio consists of multiple early-stage drug discovery and development candidates in a variety of therapeutic areas, including oncology, pain and inflammation, among others. Several assets are ready to enter clinical trials. The IND for the lead asset in the portfolio (an NCE for prostate cancer) has been approved by the US FDA.

**About the Amneal Alliance of Companies**

The Amneal Alliance of Companies is a powerful union of independent companies which focus on various disciplines within the life sciences. Each company is independent of the others but is strategically aligned to bring significant value and growth potential to the alliance members through collaboration and leveraging the strength of the group.